GT Medical Technologies
Corporate brand
UnclaimedGT Medical Technologies is a U.S. medical device company whose FDA-cleared GammaTile tile-based radiation therapy is implanted at the time of brain tumor surgery.
Last updated September 26, 2026
AI crawler reads
No AI crawler has read this profile yet.
Overview
GT Medical Technologies is a United States medical device company based in Tempe, Arizona, dedicated to improving the lives of patients living with operable brain tumors. Founded by brain tumor specialists and medical device innovators, the company was created to address critical gaps in how operable brain tumors are treated and to challenge the limitations of conventional therapies. Its stated mission is to develop innovative, surgically integrated therapies designed to deliver treatment with greater precision, improve clinical outcomes, and elevate the standard of care for patients. The company's flagship and first FDA-cleared technology is GammaTile, a surgically implantable, bioabsorbable collagen tile embedded with radiation sources. GammaTile is placed directly into the tumor cavity at the time of tumor resection, delivering highly concentrated and targeted radiation from within the surgical cavity. This intraoperative approach, described by the company as tile-based radiation therapy (TBRT), is designed to reduce the risk of tumor regrowth, protect healthy surrounding brain tissue, and limit potential side effects associated with traditional external beam radiation therapy (EBRT), such as hair loss, fatigue, and cognitive impairment. GammaTile is marketed as the first and only tile-based radiation therapy for the treatment of operable brain tumors. GT Medical positions GammaTile as an alternative to the delays and limitations of conventional post-surgical radiation. According to the company, external beam radiation typically requires a two- to eight-week healing period after surgery, during which tumor regrowth can occur, and it must pass through healthy brain tissue to reach the treatment site. By beginning to deliver radiation from day one, GammaTile is intended to act at the time when remaining tumor cells are considered most vulnerable, while avoiding daily treatment visits and interruptions to patients' lives. Since its full U.S. market launch in March 2020, GammaTile has been adopted by numerous leading cancer centers across academic and community settings, reflecting growing confidence in GT Medical's approach and the clinical impact of its technology. The company continues to support ongoing clinical trials, including the ROADS randomized controlled phase 3 trial evaluating resection plus post-operative stereotactic radiation versus resection plus cesium-131 tile-based radiation therapy for newly diagnosed brain metastases, with results presented at the 2026 ASCO Annual Meeting. GT Medical Technologies is a private company led by Chief Executive Officer Per Langoe.
History
GT Medical Technologies was founded by brain tumor specialists and medical device innovators to address critical gaps in the treatment of operable brain tumors and to challenge the limitations of conventional therapies. The company is based in Tempe, Arizona, in the United States, and describes its mission as developing innovative, surgically integrated therapies designed to deliver treatment with greater precision, improve clinical outcomes, and elevate the standard of care for patients. The company's first FDA-cleared technology is GammaTile, a surgically implantable, bioabsorbable collagen tile embedded with radiation sources. GammaTile is placed directly into the tumor cavity at the time of tumor resection, delivering radiation from within the surgical cavity to provide precise, localized tumor control while limiting exposure to surrounding healthy brain tissue. The company describes this intraoperative approach as tile-based radiation therapy (TBRT) and states that it is supported by published data from multiple institutions showing strong efficacy and safety data. GammaTile achieved full U.S. market launch in March 2020. Since that launch, the technology has been adopted by numerous leading cancer centers across academic and community settings, which the company cites as reflecting growing confidence in its approach and the clinical impact of its technology. The company continues to pursue clinical evidence, including the ROADS randomized controlled phase 3 trial of resection plus post-operative stereotactic radiation versus resection plus cesium-131 tile-based radiation therapy for newly diagnosed brain metastases. Results from ROADS were presented at the 2026 ASCO Annual Meeting, reporting that, compared with standard treatment, GammaTile was associated with a lower likelihood of cancer regrowth in the treated area, fewer worrisome changes on follow-up brain MRIs, longer patient survival, and no increase in the chance of side effects. GT Medical Technologies is a private company. Its leadership team includes Chief Executive Officer Per Langoe, Chief Medical Officer and Head of Clinical Development Michael Garcia, MD, MS, Chief Financial and Strategy Officer James Leech, Chief Operating Officer Ole Mikkelsen, MBA, Chief Marketing Officer Richard Low, Chief Commercial Officer Jeff Lewis, and Senior Vice President of Operations Anthony Smith.
GammaTile achieves full U.S. market launch.
ROADS randomized controlled phase 3 trial results presented at the 2026 ASCO Annual Meeting.
Products and positioning
Developer of surgically integrated, intraoperative radiation therapy for operable brain tumors, positioned as an alternative to the delays and limitations of external beam radiation therapy.
GammaTile
An FDA-cleared, bioresorbable collagen tile embedded with radiation sources that is surgically implanted into the tumor cavity at the time of brain tumor resection, delivering tile-based radiation therapy (TBRT) directly at the source.
Recent events
Sources6 sources
Cite this profile: Cite the canonical profile. /brand-wiki/gt-medical-technologies · Editorial policy · How profiles are compiled